Eloxatin
Anus Neoplasms
Blokhin's Russian Cancer Research CenterPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Anus Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MITOMYCINS Blokhin's Russian Cancer Research Center | Phase 3 | B |
Capecitabine Blokhin's Russian Cancer Research Center | Phase 3 | B |
Aijp (Arnebia Indigo Jade Pearl) University of California, San Francisco | Phase 2 | B |
18f-flt John M. Buatti | Phase 2 | CCC |
Ganciclovir Gene Surgery LLC | Phase 1 | CC |
INTERFERON-ALFA-2A | Phase 1 | CC |
Stimotimagene Copolymerplasmid Gene Surgery LLC | Phase 1 | CC |
Isotretinoin | Phase 1 | CC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →